Head-to-head · WeighScore
FitFlow vs Lttl
The verdict
FitFlow takes it — 67.6/100 to 66.1/100, but only just.
FitFlow grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FitFlow (FitFlow Health) is a 100% online compounded telehealth platform for GLP-1 weight loss - compounded semaglutide (=Wegovy) and tirzepatide (=Mounjaro). Lttl is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FitFlow | Lttl |
|---|---|---|
| WeighScore | 67.6/100 | 66.1/100 |
| Grade | C | C |
| Scorecard rank | #166 | #205 |
| Semaglutide | $175/mo (compounded) | $199/mo (all doses, compounded) |
| Tirzepatide | $235/mo (compounded) | $279/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #166 · C
Strengths
- Compounded semaglutide (=Wegovy) and tirzepatide (=Mounjaro); month-to-month from $175/$235, or as low as $99/$125 on annual prepay
- 100% online 4-step process; board-certified provider review in 24-48 hours, with unlimited messaging and dose adjustments
- Free nationwide shipping (discreet, 5-7 days) from US-licensed compounding pharmacies
- FSA/HSA eligible with financing (Affirm, Klarna, Afterpay); month-to-month or prepay plans, cancel anytime
- Transparent 'no hidden fees' pricing; 6,000+ members; same-platform add-ons (NAD+, sermorelin, MIC+B12, glutathione, hair, sexual health)
Where it loses points
- Headline '$99/$125 a month' requires a full year prepaid upfront ($1,188 / $1,500); true month-to-month is $175 / $235
- Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- The compounding pharmacy partner is not named ('US-licensed / FDA-regulated pharmacies' only)
- State-availability list is not published (free nationwide shipping advertised, but no explicit state list)
- No LegitScript certification displayed
Graded #205 · C
Strengths
- Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
- Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
- States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
- Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
- Oral ODT semaglutide offered for members who want to avoid injections
Where it loses points
- Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
- The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
- No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
- Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
- Medications cannot be returned or refunded once they ship from the pharmacy
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.